No difference in bacterial kill was observed for either carbapenem for the majority of the ESBL isolates tested, because the MICs were low ( 0.5 g/ml for meropenem; 1.5 g/ml for ertapenem). This corresponded to fT MICs of 75% and 23% for meropenem and ertapenem, respectively. For seven of the eight ESBL isolates with ertapenem
ANTIBIOTICS: CARBAPENEMS AND MONOBACTAMS. DRUG NAME, doripenem, ertapenem (INVanz), meropenem, meropenem-vaborbactam (Vabomere), imipenem–cilastatin
Other differences of Ertapenem (vs other carbapenems) is lack of activity vs Acinetobacter and Enterococci. Carbapenems (Imipenem, Meropenem, Ertapenem
Agents with anti-pseudomonal activity, including doripenem, imipenem, and meropenem, are not recommended in this population. Page 2: Ertapenem vs. Meropenem:
In this case ertapenem is less broad spectrum than meropenem, because ertapenem lacks coverage for Acinetobacter, Pseudomonas, and Enterococci. In turn, the
Agents with anti-pseudomonal activity, including doripenem, imipenem, and meropenem, are not recommended in this population. Page 2: Ertapenem vs. Meropenem:
spectrum of activity of the carbapenems, excluding ertapenem, includes The data revealed more potent activity for meropenem versus imipenem against P.
Unlike the other carbapenems, ertapenem is not active against Pseudomonas or against Acinetobacter spp. Meropenem and ertapenem are stable to the renal enzyme
meropenem, ertapenem (reliable activity vs. ESBL-producing meropenem/ertapenem Once daily aminoglycosides Selected antifungal agents
Ziegler sisters
Scout Taylor Compton versus Danielle Harris
Danielle bregoli versus woah Vicky